'Unheard-of speeds': Trump, newly warmed up to biopharma, praises industry's coronavirus response at White House meeting
Speed is of the essence when it comes to developing vaccines and therapeutics for the new coronavirus. Especially if you are briefing President Donald Trump.
“What’s your timing here?” was Trump’s go-to question after he listened to each of the 10 biopharma executives who convened in the White House Monday afternoon with the coronavirus task force led by VP Mike Pence.
The usual suspects were present: Stéphane Bancel of Moderna, which has shipped off its mRNA vaccine for a Phase I study at the NIH; Len Schleifer of Regeneron, in the hunt for antibodies; Gilead’s Daniel O’Day, there to discuss the two Phase III trials his company has started for a closely watched antiviral; and GlaxoSmithKline CEO Emma Walmsley, together with representatives of J&J and Sanofi, representing the traditional vaccine makers.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.